A RANDOMIZED, PHASE III STUDY OF RILVEGOSTOMIG IN COMBINATION WITH FLUOROPYRIMIDINE AND TRASTUZUMAB DERUXTECAN VERSUS TRASTUZUMAB, CHEMOTHERAPY, AND PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF HER2-POSITIVE GASTRIC CANCER (ARTEMIDE-GASTRIC01)
- Registry ID
- D702AC00001
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ASTRAZENECA CANADA INC
- Start date
- 2025-02-13
- Last update
- 2024-07-26
Conditions
Related clinical trials
- ROSETTA GASTRIC-204: A BLINDED, RANDOMIZED, PHASE 2/3 STUDY OF PUMITAMIG IN COMBINATION WITH CHEMOTHERAPY VERSUS NIVOLUMAB IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
- A PHASE III, MULTICENTRE, RANDOMISED CONTROLLED STUDY OF SONESITATUG VEDOTIN IN
COMBINATION WITH FLUOROPYRIMIDINE WITH OR WITHOUT RILVEGOSTOMIG IN FIRST-LINE
CLAUDIN18.2-POSITIVE, HER2-NEGATIVE, ADVANCED/METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
(CLARITY-GASTRIC 02)
- A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF TRASTUZUMAB
DERUXTECAN (ENHERTU®) PLUS CHEMOTHERAPY PLUS OR MINUS PEMBROLIZUMAB VERSUS
CHEMOTHERAPY PLUS TRASTUZUMAB PLUS OR MINUS PEMBROLIZUMAB AS FIRST-LINE
TREATMENT IN PARTICIPANTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
HER2POSITIVE GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) CANCER (DESTINYGASTRIC05)
- A PHASE 2 RANDOMIZED STUDY TO EVALUATE THE SAFETY, EFFICACY, AND OPTIMAL DOSE OF ABBV-400 IN COMBINATION WITH FLUOROURACIL, LEUCOVORIN, AND BUDIGALIMAB AS FIRST-LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA (ANDROMETA-GEA-977)
- A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 3 TRIAL OF DOMVANALIMAB, ZIMBERELIMAB, AND CHEMOTHERAPY VERSUS NIVOLUMAB AND CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, AND ESOPHAGEAL ADENOCARCINOMA
- PIONEERING PRE- AND POST-OPERATIVE INTEGRATIVE CARE TO IMPROVE THORACIC CANCER QUALITY OF CARE: THE THORACIC PERI-OPERATIVE INTEGRATIVE SURGICAL CARE EVALUATION (POISE) TRIAL - STAGE III
View on source registry